Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...

The Golden Bullet for Drug Delivery

It’s the Holy Grail in the cannabis industry. Everyone is trying to innovate the best delivery system to optimize the “bioavailability” (uptake) of medical cannabis in order to offer the perfect pairing -- precise dosing with a fast on...

Biopharma's Technology Could Render Drug Suitable for COVID-19 Treatment

How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report. In an April 7 research note, ROTH Capital Partners analyst Jonathan Aschoff discussed the potential of app...

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

Lexicon Pharmaceuticals shares traded higher by more than 30% today after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. Yesterday afternoon, The Woodlands, Tex.-based Lexicon Pharmaceu...

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. Clinical-stage biopharmaceutical company Protago...

Texas Oilfield Services Firm 'Well Positioned for 2020'

The factors contributing to the company's status and financial expectations for this year are discussed in a Raymond James report. In a Jan. 21 research note, Raymond James analyst Praveen Narra reported that Halliburton Co. (HAL:NYSE) is "well positioned ...

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...

What Is Vanadium and Why Should I Care?

Summary Vanadium is the 20th most abundant element in the earth’s crust and the 13th most available metal, but it is a challenge to recover. Heap leaching is a method that has taken low grade deposits (gold, copper, nickel and cobalt) and recovers sufficient ...

Fiji Gold Mine Attracts 'Internationally Renowned Economic Geologist'

As Lion One moves forward with getting its low-cost, fully permitted Fiji gold mine into production, Dr. Quinton Hennigh joins the team as an advisor. Lion One's Tuvatu Gold Project The mention of Fiji conjures pictures of pristine tropical b...

Does this Device Solve the Issue of Electromagnetic Radiation?

There is a large health issue that few know about and does not see much press, but it is there for everyone to see buried in the fine print when you buy most cell phones. I am talking about electromagnetic radiation (EMR) that is emitted with electronic devices, such as...
1 2